Comparison of Glycemic Control Achieved With 2 Different Needles
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate if a 31 gauge x 6 mm needle will provide comparable blood glucose control to the 29 gauge x 12.7 mm needle in obese subjects with diabetes.
Condition or disease
DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Delivery Systems
Device: NovoFine® needle 6 mmDevice: Ultra-Fine needle 12.7 mm
Comparison of Glycemic Control Achieved With a 31 Gauge x 6 mm NovoFine® Needle vs. a BD 29 Gauge x 12.7 mm Ultra-Fine® Needle in Subjects With Diabetes Mellitus and a BMI Exceeding 30 kg/m2: An Open Label, Randomized, Two-Period Crossover Study
Study Start Date
Primary Completion Date
Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Current treatment with insulin or insulin analogues for the last 6 months
BMI greater than or equal to 30.0 kg/m2
Currently injecting in the thigh or abdomen
HbA1c below 10%
Severe, uncontrolled hypertension
Unwillingness to monitor blood glucose
Pregnancy, breast-feeding, intention to become pregnant, or inadequate contraceptive measures